Literature DB >> 26369958

Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy.

Kaylee Marino1, Anne Parlee1, Ralph Orlando2, Lori Lerner3, Judith Strymish4, Kalpana Gupta5.   

Abstract

An increase in fluoroquinolone resistance and transrectal ultrasound-guided prostate (TRUS) biopsy infections has prompted the need for alternative effective antibiotic prophylaxis. We aimed to compare ciprofloxacin and other single-agent therapies to combination therapy for efficacy and adverse effects. Men who underwent a TRUS biopsy within the VA Boston health care system with documented receipt of prophylactic antibiotics periprocedure were eligible for inclusion. Postprocedure infections within 30 days were ascertained by chart review from electronic records, including any inpatient, outpatient, or urgent-care visits. Among 455 evaluable men over a 3-year period, there were 25 infections (5.49%), with sepsis occurring in 2.4%, urinary tract infections (UTI) in 1.54%, and bacteremia in 0.44% of patients. Escherichia coli was the most common urine (89%) and blood (92%) pathogen, with fluoroquinolone resistance rates of 88% and 91%, respectively. Ciprofloxacin alone was associated with significantly more infections than ciprofloxacin plus an additional agent (P = 0.014). Intramuscular gentamicin alone was also significantly associated with a higher infection rate obtained with all other regimens (P = 0.004). Any single-agent regimen, including ciprofloxacin, ceftriaxone, or gentamicin, was associated with significantly higher infection rates than any combination regimen (odds ratio [OR], 4; 95% confidence interval [CI], 1.47, 10.85; P = 0.004). Diabetes, immunosuppressive condition or medication, hospitalization within the previous year, and UTI within the previous 6 months were not associated with infection risk. Clostridium difficile infections were similar. These findings suggest that ciprofloxacin, ceftriaxone, and gentamicin alone are inferior to a combination regimen. Institutions with high failure rates of prophylaxis for TRUS biopsies should consider combination regimens derived from their local data.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26369958      PMCID: PMC4649242          DOI: 10.1128/AAC.01457-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Ziding Feng; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance.

Authors:  Behfar Ehdaie; Emily Vertosick; Massimiliano Spaliviero; Anna Giallo-Uvino; Ying Taur; Maryellen O'Sullivan; Jennifer Livingston; Pramod Sogani; James Eastham; Peter Scardino; Karim Touijer
Journal:  J Urol       Date:  2013-09-07       Impact factor: 7.450

Review 3.  Antibiotic prophylaxis for transrectal prostate biopsy.

Authors:  Emerson L Zani; Otavio Augusto Camara Clark; Nelson Rodrigues Netto
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

4.  Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care.

Authors:  Aisha K Taylor; Teresa R Zembower; Robert B Nadler; Marc H Scheetz; John P Cashy; Diana Bowen; Adam B Murphy; Elodi Dielubanza; Anthony J Schaeffer
Journal:  J Urol       Date:  2012-02-16       Impact factor: 7.450

5.  Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use.

Authors:  Uday Patel; Prokar Dasgupta; Peter Amoroso; Ben Challacombe; James Pilcher; Roger Kirby
Journal:  BJU Int       Date:  2011-10-31       Impact factor: 5.588

6.  Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment.

Authors:  Osama M Zaytoun; Ethan H Vargo; Ramanathan Rajan; Ryan Berglund; Steven Gordon; J Stephen Jones
Journal:  Urology       Date:  2011-03-21       Impact factor: 2.649

7.  Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis.

Authors:  Mehrad Adibi; Brad Hornberger; Deepa Bhat; Ganesh Raj; Claus G Roehrborn; Yair Lotan
Journal:  J Urol       Date:  2012-10-08       Impact factor: 7.450

8.  Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?

Authors:  Alex Carignan; Jean-François Roussy; Véronique Lapointe; Louis Valiquette; Robert Sabbagh; Jacques Pépin
Journal:  Eur Urol       Date:  2012-05-03       Impact factor: 20.096

  8 in total
  7 in total

1.  Performance Validation of Selective Screening Agars for Guiding Antimicrobial Prophylaxis in Patients Undergoing Prostate Biopsy.

Authors:  Sofie C M Tops; Marlie Bruens; Sacha van Mook-Vermulst; Diane Lamers-Jansen; Tobias Engel; Ger van den Brink; Rob van Duuren; Heiman F L Wertheim; Eva Kolwijck
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

2.  Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison.

Authors:  Vassilios M Skouteris; E David Crawford; Vladimir Mouraviev; Paul Arangua; Marios Panagiotis Metsinis; Michael Skouteris; George Zacharopoulos; Nelson N Stone
Journal:  Rev Urol       Date:  2018

3.  Quality improvement initiative to reduce variability and improve stewardship of antimicrobial prophylaxis for transrectal prostate needle biopsy.

Authors:  Pedro Recabal; Taehyoung Lee; Emily Vertosick; Michael Manasia; James Eastham; Karim Touijer; Susan K Seo; Massimiliano Spaliviero; Behfar Ehdaie
Journal:  World J Urol       Date:  2019-06-12       Impact factor: 4.226

4.  Rectal E. coli above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy.

Authors:  Inari Kalalahti; Kaisa Huotari; Kanerva Lahdensuo; Eveliina Tarkka; Henrikki Santti; Antti Rannikko; Anu Pätäri-Sampo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-02       Impact factor: 3.267

5.  Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005-2013: a population-based analysis.

Authors:  K Lahdensuo; A Rannikko; V-J Anttila; A Erickson; A Pätäri-Sampo; M Rautio; H Santti; E Tarkka; M Vaara; K Huotari
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-08-16       Impact factor: 5.554

6.  Trial Comparing a Combined Regimen of Amikacin and Ciprofloxacin to Ciprofloxacin Alone as Transrectal Prostate Biopsy Prophylaxis in the Era of High Fluoroquinolone-Resistant Rectal Flora.

Authors:  Kyung Chul Son; Ho Seok Chung; Seung Il Jung; Myung Soo Kim; Eu Chang Hwang; Jin Woong Kim; Dong Deuk Kwon
Journal:  J Korean Med Sci       Date:  2018-04-09       Impact factor: 2.153

7.  CombiANT: Antibiotic interaction testing made easy.

Authors:  Nikos Fatsis-Kavalopoulos; Roderich Roemhild; Po-Cheng Tang; Johan Kreuger; Dan I Andersson
Journal:  PLoS Biol       Date:  2020-09-17       Impact factor: 8.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.